An EGFR/HER2-Targeted Conjugate Sensitizes Gemcitabine-Sensitive and Resistant Pancreatic Cancer through Different SMAD4-Mediated Mechanisms

0
91
To overcome chemoresistance in PDAC, researchers aimed to study dual-targeting ligand-based lidamycin efficacy when combined with gemcitabine and exploreed its mechanisms of action.
[Nature Communications]
Full Article